🇺🇸 FDA

Company profile · Sponsor

Regeneron

Regeneron UK Limited

REGN · NYSE pharma TARRYTOWN, NY, GB
Pipeline
24
Drugs
11
Patents
8

Quick answer

Regeneron (REGN) is a pharma company. headquartered in TARRYTOWN, NY, GB. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 11 drugs, and 8 patents to this profile..

Company facts

Ticker REGN
Exchange NYSE
Company type pharma
Headquarters TARRYTOWN, NY, GB
SEC CIK 0000872589

Pipeline (24)

Search pipeline →

  1. 2-mg Intravitreous Aflibercept Injection

    Regeneron

    Proliferative Diabetic Retinopathy

    phase 3 small molecule completed

    1 trial

  2. 2.0 mg intravitreal aflibercept

    Regeneron

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial

  3. 8 mg aflibercept (BAY 86-5321) (High Dose)

    Regeneron

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial

  4. Aflibercept

    Regeneron

    Prostatic Neoplasms

    phase 3 small molecule completed

    1 trial

  5. Aflibercept

    Regeneron

    Colorectal Cancer Metastatic

    phase 3 small molecule completed

    3 trials

  6. Aflibercept (EYLEA, BAY86-5321)

    Regeneron

    Glaucoma, Neovascular

    phase 3 small molecule completed

    1 trial

  7. Aflibercept (Eylea, BAY 86-5321)

    Regeneron

    Glaucoma, Neovascular

    phase 3 small molecule completed

    1 trial

  8. Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

    Regeneron

    Macular Edema

    phase 3 mab completed

    1 trial

  9. Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

    Regeneron

    Macular Degeneration

    phase 3 mab completed

    1 trial

  10. Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)

    Regeneron

    Carcinoma

    phase 3 small molecule completed

    1 trial

  11. Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)

    Regeneron

    Pancreatic Neoplasm

    phase 3 small molecule terminated

    1 trial

  12. Aflibercept 8 mg

    Regeneron

    Neovascular Age-Related Macular Degeneration

    phase 3 small molecule active

    1 trial

  13. Aflibercept AVE0005

    Regeneron

    Colorectal Cancer Metastatic

    phase 3 small molecule terminated

    2 trials

  14. Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)

    Regeneron

    Neovascular Age-Related Macular Degeneration

    phase 3 small molecule completed

    1 trial

  15. Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)

    Regeneron

    Retinal Vein Occlusion

    phase 3 mab completed

    1 trial

  16. Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose

    Regeneron

    Macular Edema Secondary to Retinal Vein Occlusion

    phase 3 small molecule completed

    1 trial

  17. Alirocumab

    Regeneron

    Homozygous Familial Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  18. Alirocumab

    Regeneron

    Hypercholesterolaemia

    phase 3 small molecule completed

    2 trials

  19. Alirocumab

    Regeneron

    Hypercholesterolemia

    phase 3 small molecule active

    18 trials

  20. Alirocumab

    Regeneron

    Coronary Vessel

    phase 3 small molecule completed

    1 trial

  21. Alirocumab

    Regeneron

    Atherosclerotic Cardiovascular Disease

    phase 3 small molecule completed

    1 trial

  22. Alirocumab

    Regeneron

    Type2 Diabetes

    phase 3 small molecule completed

    1 trial

  23. Alirocumab 150 MG/ML [Praluent]

    Regeneron

    Hemodialysis

    phase 3 small molecule active

    1 trial

  24. Alirocumab SAR236553

    Regeneron

    Hypercholesterolaemia

    phase 3 small molecule completed

    1 trial

Drugs (11)

Search drugs →

  1. aflibercept

    SKOJOY

    INJECTION approved

    S01LA05

  2. alirocumab

    PRALUENT

    INJECTION approved

    C10AX14

  3. atoltivimab

    INMAZEB

    INJECTION approved

  4. cemiplimab

    LIBTAYO

    L01XC33

  5. cemiplimab-rwlc

    LIBTAYO

    INTRAVENOUS approved

  6. dupilumab

    DUPIXENT

    INJECTION approved

    D11AH05

  7. evinacumab-dgnb

    EVKEEZA

    INJECTION approved

  8. linvoseltamab

    LYNOZYFIC

    L01FX

  9. odronextamab

    ORDSPONO

    Not yet assigned

  10. pozelimab-bbfg

    VEOPOZ

    INJECTION approved

  11. rilonacept

    RILONACEPT FGK REPRESENTATIVE SERVICE GMBH

    SINGLE-USE approved

    L04AC04

Patents (8)

Search patents →

  1. US 12421512

    CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12421315

    CLL-1 targeted immunotherapies

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12419963

    Diels-Alder conjugation methods

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12421317

    Polynucleotides encoding anti-glucagon-like peptide 1 receptor (GLP1R) antagonist antibodies

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12415856

    EGFR x CD28 multispecific antibodies

    Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12410442

    Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12404505

    Delivery of a gene-editing system with a single retroviral particle and methods of generation and use

    Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12402611

    Genetically modified mice and engraftment

    Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Regeneron?

Regeneron (REGN) is a pharma company. headquartered in TARRYTOWN, NY, GB. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 11 drugs, and 8 patents to this profile..

What pipeline programs does Regeneron sponsor?

We track 24 ClinicalTrials.gov-linked programs for Regeneron, including 2-mg Intravitreous Aflibercept Injection and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Regeneron company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.